Malation

Quick links to important sections

Malation

Treatment option: Head Lice, Lice

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Malation

What is Malation? Defining the Ectoparasiticide

Property Description
Active ingredient Malathion
Form Topical liquid, lotion, shampoo
Pharmacological class Ectoparasiticide, Cholinesterase Inhibitor
Common use Eliminating parasitic infestations (e.g., lice, mites)
Origin Synthetic compound (Organophosphorus)

The medication Malation is a specialized, synthetic compound containing the active ingredient Malathion, designed exclusively for the topical route of administration. Its chemical structure places it within the organophosphorus compound class. Malathion is categorized within the cholinesterase inhibitor Pharmacologic Class.

This drug is designated as an ectoparasiticide and pediculicide, confirming its primary therapeutic role in eliminating parasites that infest the skin or scalp. Malathion is a potent agent against lice, recognized for its efficacy even against certain strains resistant to other common treatments. This means the medication offers a therapeutic option when standard therapies might fail to resolve the infestation.


Malathion Composition and Topical Forms

Malation is formulated as a single-ingredient product, available in presentations such as a topical liquid, lotion, or shampoo. The active substance, Malathion, is chemically known as O,O-dimethyl S-[1,2-bis(ethoxycarbonyl)ethyl] phosphorodithioate.

To ensure optimal performance, the formulation typically incorporates an appropriate vehicle, such as an alcoholic base or an aqueous emulsion. This formulation enhances the ability of the active organophosphorus compound to dissolve and penetrate the protective layers of the parasites and their eggs, facilitating contact and absorption across the affected area.


General Purpose of the Malathion Drug Class

The general purpose of the Malathion drug class is to terminate external parasitic life cycles. This is achieved through its primary mechanism as an anticholinesterase agent, which causes the disruption of the parasite's nervous system.

This specific neurotoxic action leads to the paralysis and death of the target organisms. Malathion has an established role as a reliable therapeutic tool for managing parasitic diseases in humans. This utility underscores the role of the drug class for resolving persistent infestations caused by lice or mites.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Malation?

Possible Side Effects and Safety Information

The officially documented safety profile of Malathion topical lotion is organized around local application-site reactions and critical safety restrictions, as stipulated by government regulatory agencies.


Adverse Reaction Scope

Feature Regulatory Documentation Summary
Key Adverse Reaction Categories Local cutaneous reactions; Serious burns; Potential for systemic toxicity from accidental ingestion.
System-Organ Classes Involved Skin and Subcutaneous Tissue Disorders (e.g., irritation, burns); Eye Disorders (e.g., mild conjunctivitis from accidental contact).
Serious Adverse Reactions Chemical burns, including second-degree burns; Symptoms of acute systemic toxicity (e.g., excessive cholinergic activity) resulting from accidental oral ingestion or gross over-exposure.

Population-Specific and Flammability Constraints

Feature Regulatory Documentation Summary
Population-Specific Safety Contraindicated in neonates and infants due to the risk of increased systemic absorption through more permeable skin. Safety and effectiveness are not established in children under 6 years.
Safety-Related Restrictions Flammability Risk: The lotion and hair wet with the lotion must not be exposed to open flames, electric heat sources, or smoking. Contraindicated in individuals with known sensitivity to malathion or any component of the vehicle.

The regulatory safety structure confirms that the primary reported adverse reactions are localized irritation and stinging at the application site. The framework highlights the serious documented risks of chemical burns and the critical restriction concerning the flammable nature of the product. This information clearly defines the boundaries of use, including the explicit contraindication for neonates and infants.

Overdose and Emergency Response

Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations Overdose is classified as systemic organophosphate poisoning due to excessive cholinergic activity and cholinesterase depletion.
Physiological systems affected Respiratory, Cardiovascular, Gastrointestinal, Neuromuscular, and Central Nervous System are affected.
Dose-related or exposure-related factors The major risk is associated with accidental oral ingestion of the topical solution.
Population-specific overdose notes No specific, unique considerations for different populations are explicitly detailed in the official topical malathion regulatory labels.
Emergency-response statements Contact the Poison Help hotline for treatment guidance.
When immediate medical help is required Seek medical attention immediately in case of accidental ingestion. If the person has collapsed or is not breathing, call emergency services.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification Associated with potentially life-threatening outcomes, with severe respiratory distress being the most serious symptom.
Regulatory basis Based on approved Prescribing Information and Summary of Product Characteristics (SmPC).
Overdose-context constraints Consideration should be given to the presence of a high concentration of isopropyl alcohol in the topical vehicle.

Resulting Overdose Structure

Official overdose statements:

  • Symptoms of severe toxicity include apnea, coma, convulsions (seizures), severe respiratory distress, and pinpoint pupils (miosis).
  • Management may require specific antidotes, such as atropine and pralidoxime, as described in the product labeling.
  • Supportive measures documented include inducing vomiting or performing gastric lavage, and providing artificial respiration.
  • Healthcare providers are advised to measure and monitor vital signs.

Connection to the overall overdose profile (2–4 sentences): The regulatory documents strictly define the Malation overdose profile based on its pharmacological class, resulting in a systemic cholinergic crisis after accidental ingestion. The profile mandates immediate, urgent medical action due to the potential for severe respiratory and neurological compromise. The official structure specifies the procedural interventions and the use of documented antidotes required for management.

Therapeutic Uses of Malation

What Malathion Treats: Main Uses and Benefits

Malathion topical lotion is commonly used across conditions presenting with acute episodes of parasitic infestation. The primary therapeutic use is applied across therapeutic domains involving treating head lice (Pediculus humanus capitis) and their eggs (ova). Malathion is classified as a pediculicide and is applied in addressing symptom clusters associated with this type of condition.

The medication contributes to easing the overall symptom load, is used for managing the associated symptoms, and plays a role in managing symptoms that interfere with daily comfort, such as intense scalp itching and irritation. This supportive symptom management is appropriate for individuals experiencing symptoms related to inflammatory or irritative states on the scalp. The medication assists with maintaining functional stability and may help patients cope more steadily with the presence of these disruptive symptoms. This treatment is relevant for easing discomfort in clinical scenarios marked by temporary physiological imbalance.

Quick Fact: Supports comfort during periods of Intense Scalp Itching

Regulatory References

  1. NIH MedlinePlus overview on Malathion

Eligibility and Restrictions for Use

The eligibility for using Malathion topical lotion is strictly defined by regulatory guidelines, primarily based on age and hypersensitivity.

Contraindicated and Restricted Populations

The medicine is contraindicated and must not be used by neonates and infants, as regulatory documents cite their scalps are more permeable, increasing the potential for systemic absorption. Use is also strictly prohibited for individuals with a known hypersensitivity or allergy to Malathion or any component of the lotion formulation.


Age-Based Eligibility

The medicine is officially approved for use in adults and children 6 years of age and older. The safety and effectiveness of the lotion have not been established in children under 6 years of age, and use in children younger than 2 years of age is generally not recommended. No specific data is available regarding the effects of the topical formulation in geriatric patients.


Pregnancy and Lactation Status

For pregnant individuals, the medicine is classified as Pregnancy Category B and should be used only if clearly needed. Regulatory caution is advised for nursing mothers, as it is not known if Malathion is excreted in human milk.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Malathion

Interaction Scope

Category Official Regulatory Information
Medicinal product categories with documented interactions: Cholinesterase inhibitors (for pharmacodynamic risk), Carboxylesterase inhibitors (for exposure risk), and Alcohol-containing substances (for physical flammability risk).
Specific interacting medicines (if explicitly listed): No specific oral or systemic medicines are explicitly listed as having a formal interaction in official regulatory labels.
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic interaction (additive anticholinesterase effect), and Kinetic interaction involving the inhibition of carboxylesterase leading to increased systemic exposure.
Timing-based interaction rules (if applicable): None explicitly stated for separation between Malathion application and other medicinal products. Flammability constraint requires keeping product/hair away from heat until dry.
Population-specific interaction notes (if applicable): None explicitly stated as population-specific that modifies the drug–drug interaction profile.
Interaction-related restrictions: Prohibited exposure to heat sources and open flames until the topical product or treated hair is completely dry, due to the alcohol content in the formulation.

Interaction Classifications (High-Level)

Classification Official Regulatory Information
Interaction severity classification (as defined in official documents): The interaction with other cholinesterase inhibitors is classified as carrying a risk of enhanced toxicity.
Regulatory basis (EMA / FDA / etc.): FDA Prescribing Information, NIH MedlinePlus, and European national agency SmPCs.
Interaction-context constraints (as defined in official documents): The flammability restriction is a procedural constraint based on the presence of alcohol in the formulation vehicle.

Resulting Interaction Structure

Official Interaction Statements:

  • Co-administration with substances that possess cholinesterase inhibiting activity may result in an additive anticholinesterase effect, increasing the potential for systemic toxicity.
  • The use of Malathion with compounds that inhibit the detoxification enzyme carboxylesterase has the potential to cause increased Malathion systemic exposure.
  • Due to the alcohol content in the topical formulation, the product and treated hair are considered flammable. Regulatory documents strictly mandate keeping the product and wet hair away from open flames and electric heat sources until the hair is entirely dry.

Connection to the overall interaction profile

Regulatory documents define the product's interaction structure primarily around the risk of additive anticholinesterase toxicity stemming from its core pharmacological activity and the potential for impaired clearance if carboxylesterase enzymes are inhibited. The remaining documented restriction is a procedural safety constraint related to the flammability risk posed by the alcohol-based topical vehicle.

Mechanism of Action

Malathion is an organophosphate pro-drug that undergoes bioactivation, primarily in the liver, where it is converted into the oxygen analog malaoxon. Malaoxon is the biologically active metabolite that targets the nervous system. Its mechanism centers on the irreversible inhibition of the enzyme acetylcholinesterase (AChE).

Malaoxon acts as a mechanism-based covalent inhibitor, binding tightly to the serine hydroxyl group within the active site of the AChE enzyme. This modification prevents AChE from fulfilling its function of hydrolyzing the neurotransmitter acetylcholine (ACh). The consequent failure of ACh metabolism results in the persistent accumulation of unhydrolyzed acetylcholine within the synaptic clefts and neuromuscular junctions. This excess ACh continually stimulates cholinergic receptors, causing receptor overstimulation and leading to the functional disruption of nerve signal transmission across the affected physiological systems.

Dosage and Administration Information

The administration of Malathion topical lotion (0.5%) follows a specific, short-term regimen. The route of administration is exclusively topical to the hair and scalp, with the requirement that an amount just sufficient to thoroughly wet the hair and scalp be applied. The product is designated for application to DRY hair and must remain in contact with the treated area for a specific period of 8 to 12 hours.

Usage Schedule and Procedural Constraints

The treatment protocol typically consists of a single application. A second application is permitted only if live parasitic organisms are still observed after the initial treatment, and this follow-up occurs 7 to 9 days after the first application. Following the required contact time, the treated area is washed using a non-medicated shampoo and thoroughly rinsed. A fine-toothed comb is then used to remove dead parasites and nits, completing the procedural steps.

Specific administrative rules apply to the use environment: the lotion is highly flammable, and instructions prohibit the use of electric heat sources—such as hair dryers or curlers—on the wet hair during the application and contact period. Regarding patient age, the usage is cleared for individuals 6 years of age and older, but is not recommended for infants younger than 1 year. The administration to children requires the direct supervision of an adult.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action Preclinical Findings

Preclinical research has investigated the substance's mechanism of action. This research, conducted primarily in laboratory settings and non-human models, explored biological markers related to its activity as an acetylcholinesterase inhibitor.

Efficacy Research Overview

Clinical trials have explored whether Malation is associated with changes in symptoms related to the target condition, most commonly head lice (pediculosis capitis). Studies focus on acute exacerbations and the proportion of subjects considered lice-free following treatment.

Research has explored the effect of Malation on the eradication of both live lice and nits (eggs). The trials incorporated patient-reported outcome measures (PROMs) for functional ability and quality of life.

Outcome Focus Observation Period Key Study Finding Categories
Acute Symptom Research Studies focused on a 7-day observation period. Eradication rates post-treatment and comparison to established treatments.
Long-Term Follow-up Outcomes observed over 4 to 6 weeks. Data recorded on the frequency and severity of infestations, including observations of changes in these measures.

Safety and Tolerability Data

Safety data were collected from adult and pediatric participants during the trials. Common adverse events were reported, typically involving local skin reactions or mild systemic symptoms.

  • Serious Adverse Events (SAEs): Aggregated clinical data reported the incidence of SAEs. Safety signals identified during the trials were reviewed.
  • Exclusion Criteria: The trials defined specific exclusion criteria for participation, including individuals with pre-existing severe heart conditions, pregnant women, and individuals under the age of 18 in certain study designs.

Frequently Asked Questions (FAQ)

Common questions about Malation (FAQ)

Q: Are there any specific foods or drinks to avoid while taking Malation?

A: Official documents state that because Malation is formulated in an alcohol-based vehicle, the product and treated hair are flammable. Therefore, the official regulatory label requires keeping the wet product away from alcohol-containing substances and heat sources until the hair is completely dry. No restrictions concerning specific foods or non-alcoholic drinks are listed in the official product information.

Q: How quickly does Malation typically start working?

A: The regulatory administration schedule requires the lotion to remain in contact with the hair and scalp for a specific period of 8 to 12 hours. This duration indicates the time required for the product to remain in contact with the treated area, according to the regulatory guidelines.

Q: How long does the effect of a Malation dose usually last?

A: The regulatory treatment schedule is designed for acute use. The protocol allows for a second application only if live parasites are still observed after the initial treatment, and this follow-up must occur 7 to 9 days after the first. This observation period indicates the reapplication window, which is based on an observation period of at least one week.

Q: What is the safety class or category for Malation?

A: The U.S. Food and Drug Administration (FDA) classifies Malathion topical lotion pharmacologically as a pediculicide and cholinesterase inhibitor, confirming its role in parasite elimination. For pregnancy, the medicine is described in official documents as Pregnancy Category B.

Q: Is Malation safe to use for older adults?

A: Official information states that safety and effectiveness data for the topical formulation have not been established in the geriatric (older adult) patient population. This means this population is not included in the standard efficacy data summaries.

Q: Can children or adolescents use Malation?

A: According to official regulatory documentation, the medicine is approved for use in adults and children 6 years of age and older. The use of the lotion has not been established for children under 6 years of age. Additionally, use in infants younger than 1 year is officially not recommended.

Q: Is Malation approved by the FDA?

A: The active ingredient Malathion is approved by the U.S. Food and Drug Administration (FDA) for topical use in a 0.5% lotion formulation for treating head lice and their eggs (ova), as described in the federal labeling.

Q: Why do some people say Malation didn't work for them?

A: Studies and official information indicate that treatment failure can be related to factors such as non-adherence to the required 8–12 hour application time, as well as the potential for resistance of the lice to the medication.

Q: Are the side effects of Malation usually temporary?

A: The most common adverse effects reported are local cutaneous reactions like stinging, burning, and irritation at the application site. If irritation is severe or reoccurs after a second application, regulatory documents note that a healthcare professional must be consulted.

Q: How long does a person typically need to use Malation?

A: The typical course of treatment involves a single, acute application of the product. The treatment protocol allows for a second application only if live lice are still observed after the initial treatment, and this must be separated by 7 to 9 days.

Q: Is Malation habit-forming or addictive?

A: Regulatory information does not list Malathion topical lotion as having a schedule classification related to abuse potential. Symptoms associated with acute toxicity or overdose relate to its cholinergic effects on the nervous system, not addiction or habit formation.

Q: Does Malation require any special monitoring or regular blood tests?

A: Official guidance emphasizes adherence to the administration and washout instructions to limit systemic absorption. However, the regulatory label does not explicitly mandate routine blood tests or special clinical monitoring for patients using the topical formulation as directed.

Q: Are there any known long-term side effects associated with Malation use?

A: The established regulatory safety profile primarily focuses on acute toxicity risks associated with overdose or misuse. Long-term effects from proper, short-term topical use are not prominently discussed in official documents.

Q: Is Malation available in generic form?

A: Official documents indicate that generic versions of Malathion topical lotion have been approved and are available.

Q: Does Malation affect my mood or mental state?

A: Official documents describing the risk of overdose or excessive systemic exposure (acute toxicity) mention potential central nervous system effects, such as anxiety, restlessness, confusion, or mental depression.

Q: Is it possible to be allergic to Malation?

A: The official product information lists a known hypersensitivity or allergy to Malathion or any component of the lotion formulation as a specific contraindication. For this reason, the product is contraindicated (must not be used) by individuals with such a known sensitivity.

Q: Do studies show that Malation improves quality of life?

A: Clinical trials conducted to assess the effectiveness of Malation have incorporated patient-reported outcome measures (PROMs). These measures examined changes in functional ability and quality of life in subjects during the course of the studies.

Q: Is it true that Malation is derived from a natural source?

A: The active ingredient, Malathion, is chemically defined in official regulatory documents as a synthetic compound. It belongs to the organophosphorus compound chemical class.

Q: What percentage of users report feeling better after using Malation?

A: Regulatory clinical data primarily report eradication rates from clinical trials, which represent the percentage of subjects confirmed to be free of lice and nits (eggs) at 7 days post-treatment. This data is reported as the official measure of efficacy in clinical studies.

Q: Does Malation interfere with driving or operating machinery?

A: Regulatory safety information suggests that symptoms of acute systemic toxicity (overdose) can include effects like dizziness and clumsiness or unsteadiness. The label advises adherence to the administration protocol, as systemic effects such as dizziness could potentially impair driving ability.

Q: Are there different forms (like liquid vs. pill) that Malation comes in?

A: The medication is approved and formulated exclusively for the topical route of administration. It is available as a topical liquid, lotion, or shampoo but does not come in oral forms such as a pill or capsule.

Q: If Malation doesn't work, what is the next typical step?

A: The treatment protocol permits a second application 7 to 9 days after the first if live organisms are still present. If treatment is unsuccessful after the second application, official information states that other treatment options should be considered in consultation with a healthcare professional.

Q: Is there a maximum time frame for taking Malation?

A: Given the acute nature of the condition it treats, the official protocol is limited to a short, intermittent schedule of at most two possible applications separated by 7 to 9 days. There is no maximum continuous usage time frame.

Q: Can Malation make certain existing health problems worse?

A: Regulatory information suggests that certain pre-existing conditions may increase the chance of some side effects from Malathion. Examples of such conditions include severe anemia, recent brain surgery, liver disease, or malnutrition.

Q: Is Malation generally well-tolerated?

A: Safety data collected in clinical trials reported common adverse events typically involving local skin reactions or mild systemic symptoms.

Q: Can I stop using Malation suddenly?

A: The protocol specifies that the product is designed for an acute application with a specific contact time of 8 to 12 hours, after which the treated area should be washed out using non-medicated shampoo and thoroughly rinsed.

How should Malation be stored and disposed of?

Storage and Disposal Requirements

Malathion topical lotion must be stored at controlled room temperature, typically 68 F to 77 F (20 C to 25 C). The container must be kept in its original packaging, tightly closed, and protected from direct light, excess moisture, and extreme heat.

Storage Restriction Requirement
Temperature Do not freeze; avoid temperatures above 86 F.
Flammability Store away from open flames and heat sources.
Child Safety Must be stored out of the reach of children.

When discarding, unused or expired medication must not be poured into a drain or flushed down a toilet. Consult a pharmacist or local waste authority for instructions on medicine take-back programs and disposal procedures required by local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Malation found in:

A-Z Index: